A subsidiary of the University Medical Center Hamburg-Eppendorf

Vom 24.06.2024 bis 01.07.2024 zieht unsere Klinik in ein neues Gebäude. In diesem Zeitraum sind wir nur eingeschränkt erreichbar. Vielen Dank für Ihr Verständnis.
Patient und Begleitung im Gespräch mit einem Arzt

Treatment decision for prostate cancer with an intermediate risk level

The following parameters indicate prostate cancer with an intermediate level of risk: tumour category cT2b or Gleason score 7 or PSA >10-20 ng/ml.

Radical prostatectomy

The following parameters indicate prostate cancer with an intermediate level of risk: tumour category cT2b or Gleason score 7 or PSA >10-20 ng/ml.

Surgical removal of the prostate (radical prostatectomy – RPE) is a first-line treatment option for patients with a clinically localised prostate carcinoma in all risk groups. 

Radical prostatectomy

Radiotherapy

Radiotherapy can also be a suitable first-line treatment for all risk groups. Radiotherapy administered externally (percutaneously) can also be supplemented with HDR brachytherapy. 

Martini-Klinik

Accompanies you through this topic

PD Dr. Felix Preisser
Consultant

Your questions are welcome
info(at)martini-klinik.de
+49 (0)40 7410-51300

 

HDR brachytherapy

Brachytherapy is a form of internal radiotherapy. It can be administered as low-dose rate (LDR) or high-dose rate (HDR) brachytherapy. HDR brachytherapy involves temporary implantation of a high-dose radiation source and can be used against moderately and highly aggressive tumours. In HDR brachytherapy, a radiation source is implanted under anaesthetic and then removed a few minutes later. This procedure is repeated one week later and is usually accompanied by percutaneous radiotherapy. 

Brachytherapy

Focal treatment

In most patients with a prostate carcinoma, the entire prostate has to be treated. This is because, in over 80% of cases, numerous tumour lesions are distributed throughout the entire prostate. However, if the tumour is unifocal (limited to a single lesion) or confined to a specific area (e.g. a lateral lobe), and if your PSA level is below 15 ng/ml, it can be removed in a selective, targeted procedure without having to remove the entire prostate. 

Focal treatment


Treatment decisions when prostate cancer is detected early
Treatment decisions for high-risk prostate cancer

What treatment options are available for low-risk prostate cancer?

The following parameters indicate prostate cancer with an intermediate level of risk: tumour category cT2b or Gleason score 7 or PSA >10-20 ng/ml.

Surgical removal of the prostate (prostatectomy) is a first-line treatment option for patients with a clinically localised prostate carcinoma in all risk groups. Radiotherapy can also be a suitable first-line treatment for all risk groups. Radiotherapy administered externally (percutaneously) can be supplemented with HDR brachytherapy. If the tumour is contained in a specific area, localised removal of the tumour lesion (focal treatment) may also be an option.